| Bcl-B: an "unknown" protein of the Bcl-2 family. | Bcl-B: an "unknown" protein of the Bcl-2 family.
Pervushin NV, Kopeina GS, Zhivotovsky B., Free PMC Article | 11/1/2023 |
| Nrh L11R single nucleotide polymorphism, a new prediction biomarker in breast cancer, impacts endoplasmic reticulum-dependent Ca[2+] traffic and response to neoadjuvant chemotherapy. | Nrh L11R single nucleotide polymorphism, a new prediction biomarker in breast cancer, impacts endoplasmic reticulum-dependent Ca(2+) traffic and response to neoadjuvant chemotherapy.
Duong MQ, Gadet R, Treilleux I, Borel S, Nougarède A, Marcillat O, Gonzalo P, Mikaelian I, Popgeorgiev N, Rimokh R, Gillet G., Free PMC Article | 09/6/2023 |
| Bcl2l10 induces metabolic alterations in ovarian cancer cells by regulating the TCA cycle enzymes SDHD and IDH1. | Bcl2l10 induces metabolic alterations in ovarian cancer cells by regulating the TCA cycle enzymes SDHD and IDH1.
Lee SY, Kwon J, Lee KA., Free PMC Article | 10/30/2021 |
| Bcl2l10 mediates the proliferation, invasion and migration of ovarian cancer cells. | Bcl2l10 mediates the proliferation, invasion and migration of ovarian cancer cells.
Lee SY, Kwon J, Woo JH, Kim KH, Lee KA. | 10/24/2020 |
| BCL2L10 (Nrh protein) is localized to the endoplasmic reticulum and is a poor prognostic marker linked with chemotherapy resistance in breast cancer. | Breast Cancer Targeting through Inhibition of the Endoplasmic Reticulum-Based Apoptosis Regulator Nrh/BCL2L10.
Nougarede A, Popgeorgiev N, Kassem L, Omarjee S, Borel S, Mikaelian I, Lopez J, Gadet R, Marcillat O, Treilleux I, Villoutreix BO, Rimokh R, Gillet G. | 05/25/2019 |
| marrow BCL2L10 positive cells may be a biomarker for azacitidine response and OS, with a potential impact in clinical practice. | BCL2L10 positive cells in bone marrow are an independent prognostic factor of azacitidine outcome in myelodysplastic syndrome and acute myeloid leukemia.
Vidal V, Robert G, Goursaud L, Durand L, Ginet C, Karsenti JM, Luciano F, Gastaud L, Garnier G, Braun T, Hirsch P, Raffoux E, Nloga AM, Padua RA, Dombret H, Rohrlich P, Ades L, Chomienne C, Auberger P, Fenaux P, Cluzeau T., Free PMC Article | 04/28/2018 |
| These results suggest that by inhibiting Bcl2l10 activity and promoting contact between endoplasmic reticulum and mitochondria, IRBIT facilitates massive Ca(2+) transfer to mitochondria and promotes apoptosis. | IRBIT controls apoptosis by interacting with the Bcl-2 homolog, Bcl2l10, and by promoting ER-mitochondria contact.
Bonneau B, Ando H, Kawaai K, Hirose M, Takahashi-Iwanaga H, Mikoshiba K., Free PMC Article | 11/4/2017 |
| we describe the identification of a structural genetic variant segregating with affective psychosis in a family with multiple members suffering from bipolar I disorder. Using whole-genome sequencing, we delineated the translocation breakpoints as corresponding intragenic events disrupting BCL2L10 and PNLDC1. These data warrant further consideration for BCL2L10 and PNLDC1 as novel candidates for affective psychosis. | A balanced translocation disrupting BCL2L10 and PNLDC1 segregates with affective psychosis.
Bouwkamp CG, Kievit AJ, Olgiati S, Breedveld GJ, Coesmans M, Bonifati V, Kushner SA., Free PMC Article | 09/23/2017 |
| Results found that BCL2L10 was down-regulated in human hepatocellular carcinoma (HCC) tissues; its overexpression suppresses cell growth and migration of HCC cell lines. These results suggested that BCL2L10 functions as a tumor-suppressor in HCC. | BCL2L10 inhibits growth and metastasis of hepatocellular carcinoma both in vitro and in vivo.
Bai Y, Wang J, Han J, Xie XL, Ji CG, Yin J, Chen L, Wang CK, Jiang XY, Qi W, Jiang HQ. | 09/9/2017 |
| BCLB expression was a starvation stress sensor inducing apoptosis and autophagy simultaneously in HCC cells through the adenosine monophosphate-activated protein kinase AMPK-mTOR signaling cascade. | BCLB, methylated in hepatocellular carcinoma, is a starvation stress sensor that induces apoptosis and autophagy through the AMPK-mTOR signaling cascade.
Liu X, Hu X, Kuang Y, Yan P, Li L, Li C, Tao Q, Cai X. | 08/5/2017 |
| Identification of a variant in the BCL2L10 gene as a protective factor for the development of therapy-related myeloid neoplasms and de novo myelodysplastic syndrome. | The BCL2L10 Leu21Arg variant and risk of therapy-related myeloid neoplasms and de novo myelodysplastic syndromes.
Fabiani E, Fianchi L, Falconi G, Boncompagni R, Criscuolo M, Guidi F, La Brocca A, Hohaus S, Leone G, Voso MT. | 03/26/2016 |
| polyubiquitination and proteasomal turnover dictate the expression level and anti-apoptotic capacity of Bcl-B | Polyubiquitination and proteasomal turnover controls the anti-apoptotic activity of Bcl-B.
van de Kooij B, Rooswinkel RW, Kok F, Herrebout M, de Vries E, Paauwe M, Janssen GM, van Veelen PA, Borst J., Free PMC Article | 01/25/2014 |
| Data suggest that BCL2L10 is localized predominantly to mitochondria in high-quality preimplantation embryos/blastocysts; in contrast, abnormal embryos/blastocysts exhibit extra-mitochondrial localization (cytoplasm/cell nucleus) of BCL2L10. | Subcellular dynamics of the maternal cell death regulator BCL2L10 in human preimplantation embryos.
Guérin JF, Cornut-Thibaut A, Giscard-Destaing S, Pouvreau S, Guillemin Y, Aouacheria A. | 08/31/2013 |
| Bcl-B in complex with the BH3 motif of Bim protected cells from Bax-dependent apoptotic pathways. | The restricted binding repertoire of Bcl-B leaves Bim as the universal BH3-only prosurvival Bcl-2 protein antagonist.
Rautureau GJ, Yabal M, Yang H, Huang DC, Kvansakul M, Hinds MG., Free PMC Article | 06/1/2013 |
| Bcl-B interacts with the BH3 domain of BECN1 and Bcl-B overexpression reduces autophagy triggered by a variety of pro-autophagic stimuli. | The anti-apoptotic Bcl-B protein inhibits BECN1-dependent autophagic cell death.
Robert G, Gastaldi C, Puissant A, Hamouda A, Jacquel A, Dufies M, Belhacene N, Colosetti P, Reed JC, Auberger P, Luciano F., Free PMC Article | 11/17/2012 |
| expression is predictive of azacitidine-resistance in myelodysplastic syndrome patients | BCL2L10 is a predictive factor for resistance to azacitidine in MDS and AML patients.
Cluzeau T, Robert G, Mounier N, Karsenti JM, Dufies M, Puissant A, Jacquel A, Renneville A, Preudhomme C, Cassuto JP, Raynaud S, Luciano F, Auberger P., Free PMC Article | 10/13/2012 |
| Ubqln stabilizes BCLb protein, while also promoting monoubiquitination on multiple lysine residues and relocation to the cytosol. | Ubiquitination, localization, and stability of an anti-apoptotic BCL2-like protein, BCL2L10/BCLb, are regulated by Ubiquilin1.
Beverly LJ, Lockwood WW, Shah PP, Erdjument-Bromage H, Varmus H., Free PMC Article | 03/24/2012 |
| BCL2L10 methylation is associated with myelodysplastic syndromes. | Role of BCL2L10 methylation and TET2 mutations in higher risk myelodysplastic syndromes treated with 5-azacytidine.
Voso MT, Fabiani E, Piciocchi A, Matteucci C, Brandimarte L, Finelli C, Pogliani E, Angelucci E, Fioritoni G, Musto P, Greco M, Criscuolo M, Fianchi L, Vignetti M, Santini V, Hohaus S, Mecucci C, Leone G. | 02/4/2012 |
| Loss of BCL2L10 protein expression predicts poor clinical outcome in gastric carcinoma. | Loss of BCL2L10 protein expression as prognostic predictor for poor clinical outcome in gastric carcinoma.
Xu JD, Furuya T, Cao XX, Liu XL, Li QQ, Wang WJ, Xu JW, Xu ZD, Sasaki K, Liu XP. | 04/9/2011 |
| The apoptotic gene BCL2L10 is a frequent target for aberrant promoter methylation in patients with acute leukemia, de novo and therapy-related. | Analysis of genome-wide methylation and gene expression induced by 5-aza-2'-deoxycytidine identifies BCL2L10 as a frequent methylation target in acute myeloid leukemia.
Fabiani E, Leone G, Giachelia M, D'alo' F, Greco M, Criscuolo M, Guidi F, Rutella S, Hohaus S, Voso MT. | 04/2/2011 |
| The pro-apoptotic effect of BCL2L10 and growth promotion by BCL2L10 siRNA in gastric cancer cells suggest that it may be a tumour suppressor. | BCL2L10 protein regulates apoptosis/proliferation through differential pathways in gastric cancer cells.
Xu JD, Cao XX, Long ZW, Liu XP, Furuya T, Xu JW, Liu XL, De Xu Z, Sasaki K, Li QQ. | 02/26/2011 |
| study evaluates 3D structure of Bcl-2L10 protein using homology modeling and aims to understand plausible functional and binding interactions between Bcl-2L10 with BH3 domain of BAX using protein - protein docking | Homology modeling and docking studies of human Bcl-2L10 protein.
Bhargavi K, Kalyan Chaitanya P, Ramasree D, Vasavi M, Murthy DK, Uma V. | 02/5/2011 |
| BCL2L10 is frequently silenced by promoter hypermethylation in gastric cancer. | BCL2L10 is frequently silenced by promoter hypermethylation in gastric cancer.
Mikata R, Fukai K, Imazeki F, Arai M, Fujiwara K, Yonemitsu Y, Zhang K, Nabeya Y, Ochiai T, Yokosuka O. | 10/4/2010 |
| Observational study of gene-disease association, gene-environment interaction, and pharmacogenomic / toxicogenomic. (HuGE Navigator) | Variation at the NFATC2 locus increases the risk of thiazolidinedione-induced edema in the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) study.
Bailey SD, Xie C, Do R, Montpetit A, Diaz R, Mohan V, Keavney B, Yusuf S, Gerstein HC, Engert JC, Anand S, DREAM investigators., Free PMC Article | 09/15/2010 |
| BCL2L10 Is a novel and prime candidate related to oocyte maturation, fertility, and embryo developmental competence | Oocytes and early embryos selectively express the survival factor BCL2L10.
Guillemin Y, Lalle P, Gillet G, Guerin JF, Hamamah S, Aouacheria A. | 01/21/2010 |